Articles

Effects of Educational Messaging on Urgent and Emergent Care–Seeking Behaviors Among Publicly Insured Populations

Jesse Cambon, MEng; Tristan Cordier, MS; Elizabeth L. Munnich, PhD, MPP; Andrew Renda, MD; Bobby Kapur, MD, MPH; Shkelzen Hoxhaj, MD, MPH, MBA; Meredith Williams, MD, MBA

Stakeholder Perspective

Opportunities to Improve Urgent and Emergent Care Utilization

Cody Olsen, PharmD, BCPS

Original Research, Rosacea, Dermatology

Patient Preferences and Therapeutic Satisfaction with Topical Agents for Rosacea: A Survey-Based Study

Todd Williamson, PhD, MSc; Wendy Y. Cheng, MPhil, MPH; Nora McCormick, MSc; Francis Vekeman, MA

Stakeholder Perspective

There’s Room for Improvement in Rosacea Treatment

Gary M. Owens, MD

Perspectives

20% by 2020

David B. Nash, MD, MBA

Review Article, Practice Management

Standardized Review and Approval Process for High-Cost Medication Use Promotes Value-Based Care in a Large Academic Medical System

Raghu Durvasula, MD, MHA; Janet Kelly, PharmD; Anneliese Schleyer, MD, MHA; Bradley D. Anawalt, MD; Shabir Somani, MS, MBA, RPh, FASHP; Timothy H. Dellit, MD

Stakeholder Perspective

Pharmacy & Therapeutics Committees’ New Challenge: Stewardship for Specialty Drugs

Byron C. Scott, MD, MBA

FDA Approvals, Payers' Guide

Welcome to the Ninth Annual Payers’ Guide to New FDA Approvals

FDA Approvals, Introduction, Payers' Guide

FDA Approvals in 2017 Represent a 21-Year High

FDA Approvals, Payers' Guide

FDA Approvals of Brand-Name Prescription Drugs in 2017

Payers' Guide, FDA Approvals

Xermelo (Telotristat Ethyl), First-in-Class Tryptophan Hydroxylase Inhibitor, Approved for Carcinoid Syndrome Diarrhea

Payers' Guide, FDA Approvals